Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs Pfizer Inc — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5 (market cap $534.51M), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 298.6× GraniteShares 2x Long COIN Daily ETF's market cap, and Pfizer Inc pays a 6.14% dividend while GraniteShares 2x Long COIN Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Pfizer Inc for 158 Days on average.
| CONL | PFE | |
|---|---|---|
Market Cap | $534.51M | $159.59B |
Volume | 15,212,221 | 30,937,010 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $29.02 |
52-Week Low | $3.93 | $23.67 |
Typical Hold Time | 15 Days | 158 Days |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) is trading at $5.23, down 7.76% with bearish technical signals from moving averages. The ETF tracks Coinbase stock with 2x daily leverage, making it highly volatile. Recent news highlights significant price gaps and performance volatility, with one article noting an 85% decline when Coinbase fell 50%.
The outlook remains high-risk due to leveraged exposure to Coinbase volatility. Investment opportunity exists for speculative traders betting on Coinbase rebounds, but risks include amplified losses, tracking error, and crypto market sentiment swings. Caution is warranted given the bearish technical setup and leveraged structure.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
